IMGN632

Phase 2Small molecule

IMGN632 is one of 55 small molecule programs targeting Blastic Plasmacytoid Dendritic Cell Neoplasm. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Blastic Plasmacytoid Dendritic Cell NeoplasmActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Blastic Plasmacytoid Dendritic Cell NeoplasmPreclinical

Active, not recruiting

Acute Myeloid LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

59 2

Novantrone

Pfizer

Phase 3

34 3

Xospata

Astellas

Phase 3

24 4

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

42 5

Vepesid

AAvyxa

Phase 3

52 6

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 7

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 8

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

30 9

Cellcept

Busulfex

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT03386513

Q1 2027

Phase 1/2Active, not recruiting

Acute Myeloid Leukemia

NCT04086264

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting· AbbVie logo

AbbVie·Phase 1/2·NCT04086264·218 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm1 trial

A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies

Active, not recruiting· AbbVie logo

AbbVie·Preclinical·NCT03386513·179 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IMGN632. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IMGN632 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IMGN632. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AbbVie

IMGN632

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Blastic Plasmacytoid Dendritic Cell Neoplasm1 trial

References

Drug Info

Quick Facts

Related News